ArticleJournal of neuro-oncology2010
Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma.
Article in Journal of neuro-oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial.Journal of neuro-oncology · 2018Trial
- MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system.PloS one · 2014Trial
- Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Trial
- Morphological, immunophenotypic and neuroradiological characteristics of primitive B-large cell diffuse lymphoma of the central nervous system: A retrospective cohort analysis.Oncology letters · 2025Article
- Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict chemotherapeutic responses and survival in primary central-nervous-system lymphoma.European radiology · 2021Article
- New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL).Brain and behavior · 2021Article
- Performance of diffusion and perfusion MRI in evaluating primary central nervous system lymphomas of different locations.BMC medical imaging · 2020Article
- Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India.Surgical neurology international · 2020Article
- Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray.Blood advances · 2019Article
- Molecular profiling of primary central nervous system lymphomas - predictive and prognostic value?Current opinion in neurology · 2019Review
- Prognostic significance of immunohistochemical subtypes based on the stage of B-cell differentiation in primary CNS lymphoma.International journal of clinical and experimental pathology · 2019Article
- Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: Analysis of 89 cases.Oncology letters · 2017Article
- Article
- Observational
- Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.Neuro-oncology · 2015Article
- Primary central nervous system diffuse large B-cell lymphoma in the immunocompetent: Immunophenotypic subtypes and Epstein-Barr virus association.Journal of neurosciences in rural practice · 2015Article
- Risk factors for intraocular involvement in patients with primary central nervous system lymphoma.Journal of neuro-oncology · 2014Article
- LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.British journal of haematology · 2014Review
- Different spatial distribution between germinal center B and non-germinal center B primary central nervous system lymphoma revealed by magnetic resonance group analysis.Neuro-oncology · 2014Article
- Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several biomarkers have been identified as prognostic factors in primary central nervous system lymphoma (PCNSL). However, the correlation between the histogenetic origin of PCNSL and the response to therapy is still unclear. To elucidate the utility of immunophenotypic markers in predicting clinical outcomes, we investigated 27 immunocompetent patients with PCNSL treated with high-dose methotrexate therapy. Of the 27 patients, 25 received whole-brain radiotherapy after high-dose methotrexate. Immunostaining for CD5, CD10, BCL-6, and MUM-1 was used to determine the immunophenotypic profile of diffuse large B-cell lymphoma of PCNSL. We then evaluated whether immunophenotypic markers were associated with the response to therapy or patients' survival. The response to induction high-dose methotrexate therapy was determined by magnetic resonance imaging after three courses of i.v. high-dose methotrexate. We categorized B-cell lymphomas into three known subtypes: germinal center B-cell (GCB), activated-GCB, and post-GCB subtypes according to immunohistochemical profile. All the BCL-6-positive samples were co-positive for MUM-1 and therefore classified into activated-GCB subtype. BCL-6 expression in this study was associated with poor progression-free survival (P = 0.038). No immunophenotypic markers or subtypes had a significant effect on the response to high-dose methotrexate therapy. However, the response itself was a significant predictor for both progression-free survival (P < 0.001) and overall survival (P = 0.003). Further investigation is needed to assess BCL-6 as a potential prognostic factor in PCNSL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.